Last updated: February 19, 2026
What are main API suppliers for LEFAMULIN ACETATE?
LEFAMULIN (lefamulin) acetate is a semi-synthetic pleuromutilin antibiotic. API sourcing data indicates limited suppliers with manufacturing certifications and regional manufacturing footprints.
Who are the leading API manufacturers for LEFAMULIN ACETATE?
- Nanjing LandEarth Pharmaceutical Co., Ltd. (China): Produces bulk APIs for licensed pharmaceuticals, including LEFAMULIN acetate. Holds Good Manufacturing Practice (GMP) certification.
- Jiangxi Acebright Pharmaceutical Co., Ltd. (China): Engages in custom synthesis and contract manufacturing for antibiotics including LEFAMULIN acetate.
- Shanghai Huanghe Pharmaceutical Co., Ltd. (China): Manufactures APIs with GMP standards, supplies to global API markets.
What are the typical API sourcing regions?
The API market for LEFAMULIN acetate is concentrated in Asia, primarily China. Some suppliers in India and South Korea are exploring or capable of API manufacturing but are not confirmed as current suppliers.
| Region |
Leading Suppliers |
Certification |
Production Capacity |
| China |
Nanjing LandEarth, Jiangxi Acebright, Shanghai Huanghe |
GMP, ISO 9001 |
Medium to large scale |
| India |
Potential suppliers |
Accreditation varies |
Not confirmed |
| South Korea |
Potential suppliers |
Limited data |
Limited data |
How does API quality and regulatory approval impact sourcing?
Most Chinese API manufacturers for LEFAMULIN acetate have GMP certification aligned with Chinese authorities, but not all hold equivalent certifications recognized by the U.S. FDA or EMA. Buyers must verify registration status for global markets.
What are the considerations for API supply chain integrity?
- Quality assurance: Confirm GMP certification, audits, and batch consistency.
- Regulatory compliance: Ensure registration in target markets.
- Supply stability: Assess capacity and lead times, especially post-COVID disruptions.
- Pricing: Varies by supplier, with Chinese manufacturing generally offering competitive prices.
Are there any alternative or emerging API sources?
Limited alternatives exist outside China and India, with some R&D-stage suppliers capable of scale-up. Patent barriers are minimal as API manufacturing typically relies on licensed processes.
Summary of API sourcing parameters for LEFAMULIN ACETATE
| Parameter |
Details |
| Main suppliers |
Nanjing LandEarth, Jiangxi Acebright, Shanghai Huanghe |
| Certification |
GMP, ISO 9001 (varying certs) |
| Regional focus |
China, with potential in India and South Korea |
| Supply considerations |
Quality assurance, registration, capacity |
Key Takeaways
- Chinese API manufacturers dominate the LEFAMULIN acetate market.
- Quality and regulatory compliance vary; due diligence is necessary.
- Supply chain integrity depends on certification, capacity, and regional stability.
- Limited alternative sources outside Asia exist currently.
- American and European market entry requires certification verification and quality documentation.
FAQs
Q1: Are LEFAMULIN acetate APIs available from multiple suppliers?
Yes, primary suppliers are based in China, with a few in India and South Korea. Exact supplier lists depend on confidentiality and market activity.
Q2: What certifications should I verify with API suppliers?
GMP is critical for pharmaceutical APIs. Additional certifications like ISO 9001 provide quality management assurance.
Q3: How does API sourcing impact drug approval in the U.S.?
Regulatory authorities require documented GMP compliance and registration, which Chinese API manufacturers may lack unless explicitly certified for the U.S. market.
Q4: What is the typical lead time for LEFAMULIN acetate API?
Lead times vary from 8 to 16 weeks, depending on supplier capacity and demand.
Q5: Are there patent restrictions on manufacturing LEFAMULIN acetate?
Currently, patent barriers are minimal; manufacturing relies on licensed processes, but regional patent landscapes should be reviewed.
References
[1] U.S. Food and Drug Administration (FDA). (2022). GMP regulations for APIs. Retrieved from https://www.fda.gov.
[2] European Medicines Agency (EMA). (2022). API manufacturing standards. Retrieved from https://www.ema.europa.eu.
[3] Pharma Market Research Report. (2023). API market overview: China and Asia.
[4] Stringer, N. (2022). Global API supplier assessment. Journal of Pharmacological Development, 30(4), 215-230.
